3,965 Shares in AbbVie Inc. $ABBV Bought by Strathmore Capital Advisors Inc.

Strathmore Capital Advisors Inc. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,965 shares of the company’s stock, valued at approximately $1,015,000. AbbVie accounts for 0.3% of Strathmore Capital Advisors Inc.’s investment portfolio, making the stock its 22nd biggest holding.

Several other hedge funds have also recently bought and sold shares of ABBV. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie in the 4th quarter valued at $28,000. Imprint Wealth LLC raised its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the fourth quarter worth about $31,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, Marquette Asset Management LLC boosted its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Up 0.2%

Shares of ABBV stock opened at $256.08 on Monday. The firm has a 50 day moving average of $252.66 and a 200-day moving average of $228.91. The company has a market cap of $452.44 billion, a price-to-earnings ratio of 72.34, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is owned by company insiders.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn’s Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Bank of America boosted their price objective on AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Cantor Fitzgerald upped their target price on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Weiss Ratings raised AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Finally, Barclays raised their price objective on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.